Important clinical trial data would include well-designed mechanistic placebo-controlled trials of ACE2 activity and function before and following the administration of ACE-inhibitors and ARBs and large trials on the relationship between ACE2 and Ang(1–7) expression/activity on severity of infection in patients who have presented with a positive test for COVID-19. This evidence concerns the gene ACE2 and COVID-19.